The recent advances of PD-1 and PD-L1 checkpoint signaling inhibition for breast cancer immunotherapy - PubMed

Affiliations

• PMID: 33460617
• DOI: 10.1016/j.ejphar.2021.173867

Review

The recent advances of PD-1 and PD-L1 checkpoint signaling inhibition for breast cancer immunotherapy

Patience Setordzi et al. Eur J Pharmacol. 2021.

Abstract

Over the past decade, there has been sustained research activity on programmed death-1/programmed death-ligand 1 (PD-1/PD-L1) immune checkpoint inhibitors for breast cancer (BC) immunotherapy. Several clinical studies have demonstrated the anti-tumor efficacy of monotherapy drugs targeting PD-1 and PD-L1 checkpoint signaling in BC. Besides, the combination of anti-PD-1/PD-L1 agents with other inhibitors, including poly-adenosine diphosphate-ribose polymerase (PARP) inhibitors, vaccines, mitogen-activated protein kinase (MEK) inhibitors, and cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) inhibitors are being investigated to improve drug efficacy. These trials have performed well and have shown better and more sustainable therapeutic responses. As follows, the purpose of this review is to discuss the recent advances in BC immunotherapy targeting the inhibition of PD-1/PD-L1 immune checkpoint signaling, when recommended as a monotherapy or in conjunction with other treatments. We look forward to providing new insights into the current state of BC research and the future direction of PD-1/PD-L1 immune checkpoint signaling.

Keywords: Breast cancer; Combination therapies; Immunotherapy; Monotherapy; PD-1/PD-L1.

Similar articles

• Study and analysis of antitumor resistance mechanism of PD1/PD-L1 immune checkpoint blocker.

  Wang Z, Wu X. Wang Z, et al. Cancer Med. 2020 Nov;9(21):8086-8121. doi: 10.1002/cam4.3410. Epub 2020 Sep 2. Cancer Med. 2020. PMID: 32875727 Free PMC article. Review.

• Clinical Development of PD-1/PD-L1 Inhibitors in Breast Cancer: Still a Long Way to Go.

  Barroso-Sousa R, Tolaney SM. Barroso-Sousa R, et al. Curr Treat Options Oncol. 2020 Jun 17;21(7):59. doi: 10.1007/s11864-020-00756-6. Curr Treat Options Oncol. 2020. PMID: 32556894 Review.

• Research progress of PD-1/PD-L1 immunotherapy in gastrointestinal tumors.

  Sun J, Zheng Y, Mamun M, Li X, Chen X, Gao Y. Sun J, et al. Biomed Pharmacother. 2020 Sep;129:110504. doi: 10.1016/j.biopha.2020.110504. Epub 2020 Jul 8. Biomed Pharmacother. 2020. PMID: 32768978 Review.

• Progress and prospects of immune checkpoint inhibitors in advanced gastric cancer.

  Zeng Z, Yang B, Liao Z. Zeng Z, et al. Future Oncol. 2021 Apr;17(12):1553-1569. doi: 10.2217/fon-2020-0829. Epub 2021 Jan 5. Future Oncol. 2021. PMID: 33397136 Review.

• PD-1/PD-L1 counterattack alliance: multiple strategies for treating triple-negative breast cancer.

  Zhu H, Du C, Yuan M, Fu P, He Q, Yang B, Cao J. Zhu H, et al. Drug Discov Today. 2020 Sep;25(9):1762-1771. doi: 10.1016/j.drudis.2020.07.006. Epub 2020 Jul 11. Drug Discov Today. 2020. PMID: 32663441 Review.

Cited by

• Overexpression of PKMYT1 associated with poor prognosis and immune infiltration may serve as a target in triple-negative breast cancer.

  Li H, Wang L, Zhang W, Dong Y, Cai Y, Huang X, Dong X. Li H, et al. Front Oncol. 2023 Jan 30;12:1002186. doi: 10.3389/fonc.2022.1002186. eCollection 2022. Front Oncol. 2023. PMID: 36793346 Free PMC article.

• Novel immune subtypes identification of HER2-positive breast cancer based on immunogenomic landscape.

  Huang L, Liu X, Li L, Wang L, Wu N, Liu Z. Huang L, et al. Med Oncol. 2022 May 15;39(5):92. doi: 10.1007/s12032-022-01690-3. Med Oncol. 2022. PMID: 35568771

• Polymeric Systems for Cancer Immunotherapy: A Review.

  Le TMD, Yoon AR, Thambi T, Yun CO. Le TMD, et al. Front Immunol. 2022 Feb 22;13:826876. doi: 10.3389/fimmu.2022.826876. eCollection 2022. Front Immunol. 2022. PMID: 35273607 Free PMC article. Review.

• Glycolytic enzyme HK2 promotes PD-L1 expression and breast cancer cell immune evasion.

  Lin J, Fang W, Xiang Z, Wang Q, Cheng H, Chen S, Fang J, Liu J, Wang Q, Lu Z, Ma L. Lin J, et al. Front Immunol. 2023 Jun 12;14:1189953. doi: 10.3389/fimmu.2023.1189953. eCollection 2023. Front Immunol. 2023. PMID: 37377974 Free PMC article.

• Temsirolimus Enhances Anti-Cancer Immunity by Inducing Autophagy-Mediated Degradation of the Secretion of Small Extracellular Vesicle PD-L1.

  Park SS, Kim JI, Lee CH, Bae JH, Park JM, Choe EJ, Baek MC. Park SS, et al. Cancers (Basel). 2022 Aug 23;14(17):4081. doi: 10.3390/cancers14174081. Cancers (Basel). 2022. PMID: 36077620 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Elsevier Science

• Other Literature Sources

  • scite Smart Citations

• Medical

  • MedlinePlus Health Information

• Research Materials

  • NCI CPTC Antibody Characterization Program

• Miscellaneous

  • NCI CPTAC Assay Portal